Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

In 2023, Pfizer paid $43 billion to acquire Seagen, a large biopharma company focused on cancer treatments. That acquisition ...

NEW YORK: Pfizer Inc’s proposed US$43bil (RM195bil) takeover of Seagen Inc will face an investigation from the European Union’s (EU) merger enforcer, as the bloc continues to scrutinise large ...

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission. Tukysa ...

A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by ...

Recently, Pfizer has concentrated on expanding its oncology segment, enhanced by the March 2023 acquisition of Seagen. This focus on oncology highlights the importance of research and development ...

Deakin University researchers have joined scientists from SeaGen Aquaculture and Gippsland-based biotech company Offshore Biotechnologies to undertake the largest rapid assessment of marine sponge ...

In 2023, Pfizer paid $43 billion to acquire Seagen, a large biopharma company focused on cancer treatments. That acquisition has given management confidence that it can produce as many as eight ...